Results Announced From Phase 3 Trial of a Newly Formulated Tecfidera-Like Oral Therapy for Relapsing National Multiple Sclerosis Society
July 31, 2019
July 31, 2019
NEW YORK, July 31 -- The National Multiple Sclerosis Society issued the following news:
Biogen Inc. and Alkermes plc announced top-line results of a five-week, Phase 3 study that compared gastrointestinal side effects and tolerability of oral Tecfidera(R) (dimethyl fumarate, Biogen Inc.), a disease-modifying therapy approved for relapsing forms of MS, with a newly formulated, related oral compound called diroximel fumarate.
* According to a press release, diroximel fuma . . .
Biogen Inc. and Alkermes plc announced top-line results of a five-week, Phase 3 study that compared gastrointestinal side effects and tolerability of oral Tecfidera(R) (dimethyl fumarate, Biogen Inc.), a disease-modifying therapy approved for relapsing forms of MS, with a newly formulated, related oral compound called diroximel fumarate.
* According to a press release, diroximel fuma . . .